Form D · Biotechnology
Aktis Oncology, Inc.
Boston, MA · CIK 0002035832
Offering snapshot reported Oct 2, 2024 · SEC filing
- Reported sold
- $175M Offering amount: $175M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2024 | Initial | $175,000,000 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-525672
Source: Form D, filed Oct 2, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Todd Foley | Director |
| Ken Herrmann | Director |
| Helen S. Kim | Director |
| Andrew Levin | Director |
| Oleg Nodelman | Director |
| Matthew Roden | Director, Executive |
| Shulamit Ron Bigger | Executive |
| Lloyd Segal | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
17 Drydock Avenue Suite #17 401
Boston, MA, 02210
Boston, MA, 02210